Full Papers
The co-occurrence of IgG4-related disease and malignancy: insights from a prospective cohort study
Y. Guo1, Y. Wang2, M. Lu3, H. Wang4, C. Xue5, X. Zheng6, W. Zhang7, Y. Zhao8, J. Zhang9, K. Li10, J. Zhang11, F. Huang12, J. Zhu13
- Medical school of Chinese PLA, Beijing; and Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing; and State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the Fourth Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing; and State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China.
- Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital, Beijing; and State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, China. jian_jzhu@126.com
CER18452
Full Papers
PMID: 40242911 [PubMed]
Received: 17/12/2024
Accepted : 24/02/2025
In Press: 09/04/2025
Abstract
OBJECTIVES:
This study investigates the relationship between IgG4-related disease (IgG4-RD) and malignancies, focusing on tumour distribution and risk factors for malignancy development during follow-up.
METHODS:
We analysed a prospective cohort of 278 IgG4-RD patients, including 22 with malignancies, and calculated standardised incidence ratios (SIRs). Bayesian statistical models were employed to identify risk factors.
RESULTS:
Among 278 IgG4-RD patients, 22 (7.9%) developed malignancies. Lung cancer (13.6%) was the most prevalent malignancy, with a significantly higher incidence in the follow-up group compared to the history/concurrent group (19.3% vs. 7.0%; p=0.008). Testicular cancer occurred exclusively in the history/concurrent group (3.5%) and was absent in the follow-up group (p=0.044). The overall SIR was 3.28 (95% CI: 1.31–5.58) and lymphoma exhibited a markedly high SIR of 17.63 (95% CI: 0–52.89). Elevated ESR (estimate: 0.12, 95% CI: 0.04–0.23) and more organ involvements (estimate: 1.94, 95% CI: 0.31–3.93) were identified as significant risk factors for malignancy development.
CONCLUSIONS:
IgG4-RD patients exhibit an elevated risk of specific malignancies, particularly lymphoma, with elevated ESR and greater organ involvement identified as significant risk factors for malignancy development during follow-up period.
